theMednetRegister

Nephrology

IgA Nephropathy   

Questions discussed in this category

What is your recommended sequence of therapies for achieving optimal proteinuria reduction in IgA nephropathy, especially in light of the recent approvals of sparsentan, delayed-release budesonide, and iptacopan?
Do you recommend starting iptacopan or budesonide concurrently with ACE inhibitors/ARBs or sparsentan, or do you prefer a period of monitoring before ...
3 Answers available
How do you address patient concerns regarding the necessity of REMS monitoring when prescribing sparsentan?
2 Answers available
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
2 Answers available
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
3 Answers available
How do various therapeutic approaches for IgA nephropathy target the different stages of the four-hit hypothesis?
What is the role of the APRIL in the pathogenesis of IgA nephropathy?
2 Answers available
In which patients with suspected IgA nephropathy and microalbuminuria would you recommend a kidney biopsy?
1 Answer available
Would you recommend mycophenolate mofetil for patients with progressive IgA nephropathy who do not tolerate corticosteroids?
Based on the results of the MAIN trial; Hou et al., PMID: 36745456
2 Answers available
How would you manage a patient with stable axial spondyloarthritis who develops newly active IgA nephropathy?
Is there a role for immunosuppressive medications such as TNF inhibitors in the management of IgA nephropathy in this setting?
2 Answers available


Papers discussed in this category

Kidney Int Rep, 2020 Mar 16
Spondyloarthritis-Associated IgA Nephropathy.
The New England journal of medicine, 2024 Oct 25
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.

Related Topics in Nephrology

Copyright © 2025 theMednet
All Rights Reserved.